Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Wedbush Analyst Raises Price Target for Axos Financial

Elaine Mendonca by Elaine Mendonca
January 31, 2024
in Breaking News
0
Finance_ Investing in stocks
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

On January 31, 2024, Wedbush analyst David Chiaverini expressed a Neutral rating on Axos Financial (NYSE:AX) while increasing the price target from $59 to $62. This adjustment is consistent with the overall sentiment of analysts, who have given the stock an average rating of outperform and price targets ranging from $59 to $77, as reported by Capital IQ. It is worth noting that Wedbush had previously raised Axos Financial’s price target to $65 from $60, maintaining an Outperform rating. Hence, the recent price target increase to $62 reflects the prevailing positive outlook for the company.

AX Stock Shows Strong Performance with 2.17% Rise and Positive Indicators

On January 31, 2024, AX stock demonstrated strong performance. The price of AX shares increased by $1.23 since the market last closed, representing a 2.17% rise. Furthermore, AX stock opened at $60.00, which was $3.22 higher than its previous close. Trading near the top of its 52-week range and above its 200-day simple moving average is a positive sign for AX stock. The 2.17% rise in the stock’s price since the market last closed indicates strong buying pressure on AX shares. The opening price of $60.00, which was $3.22 higher than the previous close, shows significant buying interest in AX stock at the market open. However, investors should conduct thorough research and analysis before making any investment decisions.

AX Stock Performance Soars with Impressive Revenue Growth: A Promising Investment Opportunity

Title: AX Stock Performance Soars on Impressive Revenue Growth

Introduction

On January 31, 2024, AX stock experienced a remarkable surge in performance, fueled by the company’s impressive financial results. This article will delve into the stock’s performance on January 31, 2024, based on data sourced from CNN Money.

Total Revenue Growth

AX’s total revenue for the past year stood at $1.28 billion, marking a 64.89% increase compared to the previous year. The company’s growth trajectory continued into the second quarter, with total revenue reaching $518.79 million, representing a 30.2% increase since the previous quarter.

Net Income Surge

AX’s net income also experienced a significant surge. Over the past year, AX reported a net income of $307.17 million, reflecting a 27.6% increase compared to the previous year. The company’s net income for the second quarter reached $151.77 million, showing an 83.64% increase since the previous quarter.

Earnings per Share Growth

AX’s EPS for the past year stood at $5.07, reflecting a 27.7% increase compared to the previous year. In the second quarter, the company’s EPS reached $2.62, representing an 89.61% increase since the previous quarter.

Conclusion

AX’s stock performance on January 31, 2024, showcased the company’s outstanding financial results. With total revenue increasing by 64.89% since the previous year and 30.2% since the previous quarter, AX has demonstrated its ability to capture market share and generate substantial revenue growth. The significant surge in net income by 27.6% since the previous year and 83.64% since the previous quarter further highlights AX’s successful operational strategies. Additionally, the remarkable growth in earnings per share by 27.7% since the previous year and 89.61% since the previous quarter solidifies AX’s position as a financially strong and attractive investment opportunity.

Tags: AX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Technology Robotics Markets and money

Itron and Lightwell Partner to Revolutionize Smart Street Lighting and Drive Sustainable Urban Development

ESG Ratings: A New Benchmark for Textile Companies

Manhattan Associates Inc Surpasses Expectations and Receives Positive Analyst Ratings

Anticipation Builds for United States Steels Fourth Quarter Earnings

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com